Welcome to our dedicated page for Marker Therapeut SEC filings (Ticker: MRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Marker Therapeutics, Inc. (Nasdaq: MRKR), a Houston-based clinical-stage immuno-oncology company developing multi-antigen recognizing T cell (MAR-T) therapies for hematological malignancies and solid tumors. These regulatory documents offer detailed insight into the company’s financial condition, governance, and clinical and corporate milestones.
Through Marker’s periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can examine financial statements, grant income from U.S. state and federal agencies, research and development spending related to programs like MT-601 and MT-401-OTS, and discussions of risks associated with clinical-stage biotechnology operations. Current reports on Form 8-K disclose material events, including clinical updates from the Phase 1 APOLLO study in relapsed lymphoma, initiation of the Off-the-Shelf MAR-T program in AML and MDS, financial results for specific quarters, changes in the company’s independent registered public accounting firm, and appointments to the board of directors.
Stock Titan enhances these filings with AI-powered summaries that explain key points in clear language, helping users interpret complex disclosures without reading every line of each document. Real-time updates from the SEC’s EDGAR system ensure that new MRKR filings, including 8-Ks describing clinical or corporate developments, are available promptly. Users can also review exhibits attached to filings, such as press releases and presentations referenced in 8-Ks, to understand how Marker communicates its MAR-T platform progress and strategic decisions.
For investors researching MRKR stock, this page offers a structured view of Marker Therapeutics’ regulatory history, from financial reporting and auditor changes to clinical trial disclosures and governance updates, with AI tools that highlight the most relevant information in each filing.
Marker Therapeutics (MRKR) filed its Q3 2025 10‑Q, reporting cash, cash equivalents and restricted cash of $18.9M as of September 30, 2025 and total assets of $21.7M. The quarter showed grant income of $1.23M, research and development expense of $2.35M and general and administrative expense of $1.02M, resulting in a Q3 net loss of $2.0M (basic and diluted EPS $0.12 loss).
For the nine months, grant income was $2.44M and operating expenses totaled $13.45M, including a $0.45M loss on early termination of a vendor agreement, leading to a year‑to‑date net loss of $10.46M. The company raised liquidity via ATM sales, issuing 1,624,075 shares for net proceeds of $4.5M between July 17–21, 2025 and 3,734,217 shares for net proceeds of $5.4M on August 26, 2025. Shares outstanding were 16,673,127 as of November 6, 2025.
Management states there is “substantial doubt” about the ability to continue as a going concern, though current resources are expected to fund operations through the third quarter of 2026. The company continues to advance MT‑601 manufacturing via a Cellipont SOW and reports multiple active grants, including CPRIT programs with $1.4M recorded as restricted cash and deferred revenue.
Marker Therapeutics (MRKR) appointed Kathryn Penkus Corzo to its Board, effective November 1, 2025. The Board also approved equity awards under the 2020 Equity Incentive Plan.
Ms. Corzo received 147,611 stock options at fair market value, vesting evenly over 36 months, tied to continued Board service. Separately, CEO Dr. Juan Vera was granted 250,000 stock options at fair market value, vesting annually over four years. The company noted no arrangements leading to Ms. Corzo’s selection and no related party transactions, and she will stand for re‑election at the next annual meeting.
Marker Therapeutics (MRKR) filed a Form 4 reporting a director stock option grant. The filing shows a stock option (right to buy) for 147,611 shares at an exercise price of $0.9877, granted on 10/31/2025 under the company’s 2020 Omnibus Stock Ownership Plan. The options vest in 36 equal monthly installments, subject to continued board service, and expire on 10/31/2035. Following the transaction, 147,611 derivative securities are beneficially owned, held directly.
Marker Therapeutics (MRKR) reported an insider equity award. A Form 4 discloses that Chief Executive Officer and Director Juan Vera received an employee stock option grant for 250,000 shares at an exercise price of $0.9877 per share on October 31, 2025.
Per the plan terms, 25% vests on the first anniversary of the grant date, with the balance vesting in equal annual installments over the next three years, contingent on continued service. The options expire on October 31, 2035.
Marker Therapeutics (MRKR) filed a Form 3 reporting the initial beneficial ownership for a director as of 10/31/2025. The filing states that no securities are beneficially owned.
The form was signed by /s/ Julio C. Esquivel as attorney-in-fact for Kathryn Penkus Corzo, pursuant to a power of attorney dated October 15, 2025.
Marker Therapeutics, Inc. reported that it has treated the first patient in its Off-the-Shelf (OTS) program evaluating the company’s Multi-Antigen Recognizing (MAR)-T cell therapy. This marks the initial use of its OTS MAR-T product in a clinical setting, an important step in moving the therapy from development into human testing. The update was shared through a press release dated October 6, 2025, which is included as an exhibit to the report.
Marker Therapeutics, Inc. filed a Form 8-K to share new information about its Phase 1 APOLLO study. On August 26, 2025, the company issued a press release describing progress and clinical observations from this study and furnished it as Exhibit 99.1. Marker also updated its corporate presentation, made available on its website and attached as Exhibit 99.2, and prepared a webcast presentation on the APOLLO study results, attached as Exhibit 99.3. The company states that this information is being furnished under Regulation FD and is not deemed filed for liability purposes under the federal securities laws.
Amendment No. 2 to a Schedule 13D reports that John R. Wilson, as trustee of the John R. Wilson Revocable Trust U/A DTD 08/03/2017, now beneficially owns 641,801 shares of Marker Therapeutics, Inc. common stock, representing 4.96% of the 12,938,910 shares outstanding as of August 4, 2025. The filing states the decrease to below 5% resulted from sales summarized on Schedule A. The trustee has sole voting and dispositive power over the reported shares, the source of funds is identified as OO (other), and Mr. Wilson resigned from the Issuer’s board on January 24, 2025. The statement is signed by John R. Wilson as trustee on August 20, 2025.
John R. Wilson Revocable Trust reports beneficial ownership of 659,901 shares (5.10%) of Marker Therapeutics, Inc. (MRKR). The trust holds sole voting and dispositive power over these shares. The filing states the trust originally received a large block of securities and warrants in connection with a merger with Marker Cell Therapy, Inc., and the reporting person was granted director options when joining the board. The trust sold shares in recent transactions (see Exhibit A), reducing its stake by more than 1%. Mr. Wilson resigned from the Issuer's board on January 24, 2025. All securities were acquired for investment purposes and may be reviewed or traded in the future.
Marker Therapeutics Schedule 13D Amendment No. 4 reports that a group of New Enterprise Associates entities and named managers collectively beneficially own 1,625,678 shares of Marker Therapeutics common stock, representing 12.6% of the 12,938,910 shares reported outstanding as of August 4, 2025. The Amendment states the reported ownership percentage decreased by more than 1% solely because the number of outstanding shares increased. The reporting persons disclaim beneficial ownership except for shares held of record and say NEA 16 acquired its shares for investment purposes. No transactions were effected by the reporting persons in the last 60 days and they state no present plans to pursue extraordinary corporate actions.